{
  "abstract": "Background: Respiratory syncytial virus (RSV) infects nearly all children under two years, causing mild lower respiratory tract infections (LRTIs) although serious disease, mortality and long-term recurrent wheezing can also occur.\n\nObjectives: This study evaluates the health and economic impact of various RSV prevention strategies (monoclonal antibodies [mAb] such as clesrovimab, nirsevimab, palivizumab [high risk infants only] or maternal vaccination) in infants in England and Wales.\n\nDesign: A previously published decision tree model was adapted to estimate RSV LRTIs and associated costs over one year among a cohort of infants entering their first RSV season in England and Wales.\n\nMethods: Clinical trial data were used for efficacy inputs alongside country-specific epidemiology and costs to assess the impact of year-round and seasonal mAb programs (without and with catch-up [for infants born out of season]) alongside maternal vaccination. Deterministic sensitivity analyses of incremental treatment costs and QALYs were performed.\n\nResults: Seasonal administration of clesrovimab with and without catch-up led to fewer RSV-associated LRTI cases and lower treatment costs compared to other RSV intervention strategies. Without catch-up, clesrovimab reduced RSV-LRTI cases by 18%-27% versus palivizumab, 3%-4% versus nirsevimab and 2%-13% versus maternal vaccine. With catch-up, RSV-LRTI outcomes reductions by clesrovimab were greater: 60%-70% versus palivizumab, 14%-20% versus nirsevimab, and 43%-54% versus maternal vaccination. It also reduced treatment costs by £37.0 million compared to palivizumab, £4.0 million compared to nirsevimab, and £26.0 million compared to maternal vaccination. Coverage and efficacies were the most influential parameters.\n\nConclusions: Clesrovimab is projected to substantially reduce RSV-associated clinical outcomes and costs compared to both standard of care and potential new RSV prevention measures in England and Wales.",
  "abstract_shown": true,
  "affiliations": [
    "Health Economic and Decision Sciences, MSD (UK) Ltd., London, UK",
    "Health Economic and Decision Sciences, Merck & Co., Inc., Rahway, USA",
    "Value, Access, and Devolved Nations (VAD), MSD (UK) Ltd., London, UK",
    "Health Economic and Decision Sciences, Merck Canada Inc, Kirkland, QC, Canada"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Klodeta Kura"
    },
    {
      "affs": [
        1
      ],
      "name": "Colleen Burgess",
      "orcid": "0000-0003-0393-0767"
    },
    {
      "affs": [
        2
      ],
      "name": "Ian R. Matthews"
    },
    {
      "affs": [
        1
      ],
      "name": "Salisu M. Garba"
    },
    {
      "affs": [
        1
      ],
      "name": "Dawei Wang"
    },
    {
      "affs": [
        3
      ],
      "name": "John C. Lang"
    },
    {
      "affs": [
        2
      ],
      "name": "Dionysios Ntais"
    },
    {
      "affs": [
        0
      ],
      "name": "Yao-Hsuan Chen"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/42qnr77x5srt9.bib",
  "cited_by": 0,
  "doi": "10.1177/20499361261483967",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13724907/",
  "id": "42qnr77x5srt9",
  "issns": [
    "2049-9361",
    "2049-937X"
  ],
  "landing_url": "https://doi.org/10.1177/20499361261483967",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research Article"
    ],
    [
      "openalex",
      "2713|Respiratory viral infections research"
    ]
  ],
  "openalex": "W7213497904",
  "pdf_url": null,
  "pmcid": "PMC13724907",
  "pmid": "42973728",
  "published": "2026-09-17",
  "publisher": "SAGE Publications",
  "ris": "https://research.draconitic.com/paper/42qnr77x5srt9.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T12:23:24Z",
      "native_id": "PMC13724907",
      "source": "pmc",
      "url": "https://doi.org/10.1177/20499361261483967"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2713|Respiratory viral infections research",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Modeling the potential clinical and economic impact of clesrovimab for the prevention of RSV in infants in England and Wales",
  "title_text": "Modeling the potential clinical and economic impact of clesrovimab for the prevention of RSV in infants in England and Wales",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T12:21:17Z",
  "url": "https://research.draconitic.com/paper/42qnr77x5srt9",
  "venue": "Therapeutic Advances in Infectious Disease",
  "versions": []
}